Arrowhead Pharmaceuticals/$ARWR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Ticker
$ARWR
Sector
Primary listing
Employees
609
Headquarters
Website
ARWR Metrics
BasicAdvanced
$5.7B
-
-$1.14
1.14
-
Price and volume
Market cap
$5.7B
Beta
1.14
52-week high
$43.69
52-week low
$9.57
Average daily volume
1.7M
Financial strength
Current ratio
4.868
Quick ratio
4.667
Long term debt to equity
115.54
Total debt to equity
137.222
Interest coverage (TTM)
-1.31%
Profitability
EBITDA (TTM)
-85.396
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-25.90%
Operating margin (TTM)
-18.84%
Effective tax rate (TTM)
-1.25%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
-5.96%
Return on equity (TTM)
-37.11%
Valuation
Price to revenue (TTM)
9.389
Price to book
10.91
Price to tangible book (TTM)
11.07
Price to free cash flow (TTM)
-305.284
Free cash flow yield (TTM)
-0.33%
Free cash flow per share (TTM)
-0.135
Growth
Revenue change (TTM)
2,816.21%
Earnings per share change (TTM)
-75.59%
3-year revenue growth (CAGR)
31.86%
10-year revenue growth (CAGR)
107.78%
3-year earnings per share growth (CAGR)
-8.08%
10-year earnings per share growth (CAGR)
-3.39%
What the Analysts think about ARWR
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
ARWR Financial Performance
Revenues and expenses
ARWR Earnings Performance
Company profitability
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
Business Wire2 weeks ago
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
Business Wire4 weeks ago
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals (ARWR) has a market cap of $5.7B as of November 16, 2025.
What is the P/E ratio for Arrowhead Pharmaceuticals stock?
The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of November 16, 2025.
Does Arrowhead Pharmaceuticals stock pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of November 16, 2025.
When is the next Arrowhead Pharmaceuticals dividend payment date?
Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.
What is the beta indicator for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) has a beta rating of 1.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.